Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Freedfish- let's hope you are right. The reason people are down on Ipci is lack of progress and constant failures that they never react to. I guess with that track record every one has lost confidence that odidi can move rexista, regabatin and podras forward.
Tilator - they let us know all right... By slamming us with two offerings at historic lows... Lol...
I am guessing the legal weasel words have them protected... But just my opinion.
Tilator - my point was at end of q3 they said they expected focalin revenue to continue to grow for next several quarters... For q1 focalin revenue decreased substantially. That shows no foresight or any clue what is going on in the market place.
Beach- A conflict of interest like Odidi being CEO of one pharma company and then starting another pharma company in China? LOL...LOL
Here is a concrete example of how bad management is. The excerpt below is cut and pasted directly from the 2017 Q3 report. Where IPCI said "Focalin revenues would grow over the next several quarters":
We received final approval from the FDA in November 2013 under the Company ANDA to launch the 15 and 30 mg strengths of our generic Focalin XR® (dexmethylphenidate hydrochloride extended-release) capsules. Commercial sales of these strengths were launched immediately by our commercialization partner in the U.S., Par. In January 2017, Par launched the 25 and 35 mg strengths of its generic Focalin XR® capsules in the U.S., and in May 2017, Par launched the 10 and 20 mg strengths, complementing the 15 and 30 mg strengths of our generic Focalin XR® marketed by Par. The FDA recently granted final approval under the Par ANDA for its generic Focalin XR ® capsules in the 5, 10, 15, 20, 25, 30, 35 and 40 mg strengths, and we believe Par is preparing to launch the remaining 5 and 40 mg strengths in the near future. Under the Par agreement, we receive quarterly profit share payments on Par’s U.S. sales of generic Focalin XR®. We expect revenues from sales of the generic Focalin XR® capsules to continue to grow for the next several quarters as the newly approved strengths begin to gain market share. There can be no assurance as to when or if any further launches will occur for the remaining strengths, or if they will be successfully commercialized.
Fabius- Lets hope they are actually doing something. It would nice to see them accomplish something for a change.
Volume not there. I guess no one really willing to sell at this level.
Tilator- Look at the volume today... 10,000 shares traded so far... No buying, no selling. Until IPCI starts to deliver on some of their promises, everyone has given up...
Blue - I have a hard time seeing market cap go lower as cash value of andas exceed $20m. Let's hope for good news.
Blue- I think if you look into the IPCI/Odidi China visit last year, Shawn Graham was in some of the pictures.
Blue- Not from the company. Just an opinion from someone.
wimike- I do not know. They never let us know what is going on. I could see China being very good. I don't see them being able to sell off all the assets without letting shareholders know and taking a vote.
It has been pointed out to me that Shawn Graham(guy that is on ballot to be added as director) may be very much involved in getting IPCI's Chinese venture set up and running. Let's hope that is the case and that they are executing on this right now.
wimike- Truth be told, IPCI had to have an endless stream of CRLs from the FDA in regards to their ANDAs. They like to call it back and forth communication but the truth is their applications and responses to CRLs were inadequate... And that is why all those ANDAs have not been approved. It is not the FDA's fault. It was IPCI's poor applications and inadequate responses to the CRLs...
Mopar- Performance based options and bonuses' from now on. Performance is based on profits. No profits, no options and bonuses'. The more the profits, the more the options and bonuses. But maximum amount of these performance bonuses'/options capped at 5% of their annual salary.
Fabius- I already placed my votes against all of them!
Mopar- My suggestion is no more bonuses or options until they attain profitability. They have said numerous times over the years they were getting there... But have not... So it must have been possible... No more bonuses or options until profitability is reached!
Doog- Unfortunately I don't see those large positions going after him just yet. I think soon, but not at this meeting.
Fabius- Odidi just can't face the fact that his business model is not working. He just keeps flailing away at pushing the generics forward... It seems to be a losing battle... He now is putting all effort on a Chinese venture into generics... He now feels he can save the generic pipeline by doing this. Whether this works or not, remains to be seen. I still think he should have sold off some of the generics and concentrated on Rexista, PODRAS and Regabatin. And for heavens sake, sign a partnership on Regabatin and get it moving.
I don't know. Maybe they started Rexista HAP studies but my guess is no on PODRAS. Would be nice if someone could get clarity on this.
Blue- Like I have been saying. They never do anything. I mean they got 50 people working for them. You think they could at least get the Rexista HAP tests started or PODRAS tests started. But no...
Fabius- And then he has the nerve to request more options and bonuses... Oh and add another Odidi yes man to BOD... How funny is that...
I also don't believe the board needs another of Odidi's hand picked puppets. It needs someone from Armistice. As far as China goes, I am guessing Odidi still does not know what to do. I would not be surprised to see the China deal include some type of offering, spinoff, merger... I am not getting the impression that anything that will be done will benefit IPCI shareholders. What is sad is that generics are a tough market to be in. But now IPCI intends to go to China to push into generics more and more... The latest report said they would be seeking international markets... It just appears to me they have no market foresight and are grasping at straws that worked in the past for other business'.
Fabius- I have said all along that whoever has the short position is being spoon fed info from someone. I always thought it was Roth, Proactive, Wainwright, etc. But it could just as well be IPCI management.
blue- I just voted all my shares. I voted withhold on all board members and accounting firm. I also voted against on the two items for compensation. EVERYONE GO VOTE AGAINST and WITHHOLD!
This latest report is just another failure in the long list of IPCI management failures! So vote against/withhold on everything. I took the time and voted this for all five accounts I hold shares in. So everyone else needs to as well.
Fabius- I think if you read through the report they say that competition in the Focalin space accounted for the big drop in revenues.
Doog- Here are a few questions I have:
1. What are expectations for Seroquel sales in the next 12 months? Does IPCI see the trend in those improving, getting worse or staying the same?
2. When does IPCI plan to start first human trials with PODRAS?
3. Is IPCI working on any new drugs behind the scenes? These have been alluded to in interviews. Will IPCI make any announcement on these soon?
4. Does IPCI ever plan on doing anything with Regabatin? If so what? Are there any interested partners?
5. What if anything has come from IPCI's visit to China? Is there any deals in the works there?
6. Would IPCI consider revising its bonus/incentive plan to pay out bonuses/incentives only in the event of profitable operation?
7. Any hope for Gluco and Keppra to be commercialized? Has IPCI considered just selling these approvals off?
wimike- I don't think it is OK that they keep ignoring you. I think they should answer the questions that they can. My guess is Patient is on a tight leash that Odidi is holding. I am sure I did not help the situation at all. I sent the Odidi's and Patient some very critical emails. I have not done so for a while. But just prior to them doing the last offering, I held nothing back. I am guessing they took offense to it and did not see it as constructive criticism. My main message to them is they have failed on delivering what they had said they would for years. I also pointed out to Odidi(repeatedly) that he gave an interview in February 2017 where he talked about all the applications he was working for PODRAS. My question to him was when is he going to tell shareholders what he is working on? I am guessing he took it that I felt he was just talking and had not really been working on these new developments.
Mopar- That would be great if you could go. I hope Doog and others in the Toronto area can go as well. One thing that could send a message is those attending say I am representing the following shareholders- then list the names. I certainly would like my name on that list. And then ask a series of questions. Get all the questions and IPCI comments on record. I don't think they need to be beaten up at the meeting. As long as they answer the reasonable questions we all have.
Regarding Armistice and Anson... I am guessing they won't be there. I am sure they can call Odidi any time they want directly. I suspect Armistice won't flex their muscles just yet. But with a 20% position, they are indeed watching closely.
Would be nice if someone in Toronto could go to company meeting and ask some questions. Ask for update on 2018 progress, intentions in China and what is going on with seroquol sales.
Lmao... That pr about IT upgrade odidi said they needed to upgrade network to increase productivity... Lmao... How will a network upgrade get rexista hap studies started, podras studies started and improve seroquol sales? Such a joke... And really nice to see in that pr the company is going through international expansion... Don't bother to tell shareholders but they tell the IT guy. So typical of ipci
Cjckent - boy if the best news we get is related to a network upgrade we got real problems. I did see it mention international expansion. Nice if they would share this information with shareholders before they share it with their it company... This company is more of a joke everyday.
Cjckent - boy if the best news we get is related to a network upgrade we got real problems. I did see it mention international expansion. Nice if they would share this information with shareholders before they share it with their it company... This company is more of a joke everyday.
Spinoff... Ipci China... How bad would that be... It would take those idiots five years before they shipped pill number one... Like every one said odidi is beyond slow and should be working for a university not a public company trying to make a profit.
Fabius - you beat me to it... I was about to put a negative value on odidi.
Tilator - give me your itemized valuation of ipci assets that supports $200m.
My guess at this point is if ipci is going to get bought out in next six months it would be for $50m. Let's hope there is real effort going on with getting rexista nda refiled as that could push valuation upwards.
Agreed doog that communication with shareholders got worse with patient taking over. I thought penna was really good but I really don't see what patient has done other than Three offerings in six months... Lol
My guess at this point is if ipci is going to get bought out in next six months it would be for $50m. Let's hope there is real effort going on with getting rexista nda refiled as that could push valuation upwards.
Agreed doog that communication with shareholders got worse with patient taking over. I thought penna was really good but I really don't see what patient has done other than Three offerings in six months... Lol
Wimike - but it is a big secret... Remember odidi thinks it's his company and he doesn't have to inform the people who pay his fat salary through dilution what is going on.
Fabius - odidi is joke to the market. He does not realize it yet but he has lost his baby. Better enjoy his fat salary now as he will be out soon. But he is forward thinking. He started his next scam is smart pharma. Watch... He will be soon scamming Chinese investors with that new con.